Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

L.A. McKeown

November 06, 2024

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

L.A. McKeown

November 05, 2024

News Conference News VIVA 2023

New Carotid Stent Systems Associated With Low Stroke Risk

L.A. McKeown

November 09, 2023

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

L.A. McKeown

November 04, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

L.A. McKeown

October 08, 2021

News Conference News VIVA 2021

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

L.A. McKeown

October 07, 2021

News Conference News VIVA 2020

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

L.A. McKeown

November 27, 2020

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

L.A. McKeown

November 11, 2020

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

L.A. McKeown

November 15, 2018

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

News Conference News VIVA 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

L.A. McKeown

November 09, 2018

Presentation VIVA 2018

TOBA II 12-Month Data

Presenter: William Gray

November 09, 2018

Attacking DVT With Drug-Device Combo Does Not Reduce Postthrombotic Syndrome

News Conference News VIVA 2018

VERNACULAR: A Novel Venous Stent Shows Promise for Treatment of Iliofemoral Occlusive Disease

L.A. McKeown

November 08, 2018

News Conference News VIVA 2018

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

L.A. McKeown

November 06, 2018

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

Presentation VIVA 2017

Results from the IN.PACT SFA Randomized Trial

Presenter: Peter A. Schneider

September 15, 2017

Advertisement

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

New Carotid Stent Systems Associated With Low Stroke Risk

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

TOBA II 12-Month Data

VERNACULAR: A Novel Venous Stent Shows Promise for Treatment of Iliofemoral Occlusive Disease

IMPERIAL Substudy Provides Reassurance for Benefit of Eluvia in Long Lesions

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

Results from the IN.PACT SFA Randomized Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content